Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Association of a blood culture utilization intervention on antibiotic use in a pediatric intensive care unit.

Sick-Samuels AC, Woods-Hill CZ, Fackler JC, Tamma PD, Klaus SA, Colantuoni EE, Milstone AM.

Infect Control Hosp Epidemiol. 2019 Feb 15:1-3. doi: 10.1017/ice.2019.10. [Epub ahead of print]

PMID:
30767809
2.

A Decision Tree Using Patient Characteristics to Predict Resistance to Commonly Used Broad-Spectrum Antibiotics in Children With Gram-Negative Bloodstream Infections.

Sick-Samuels AC, Goodman KE, Rapsinski G, Colantouni E, Milstone AM, Nowalk AJ, Tamma PD.

J Pediatric Infect Dis Soc. 2019 Jan 25. doi: 10.1093/jpids/piy137. [Epub ahead of print]

PMID:
30690525
3.

Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.

Tamma PD, Conley AT, Cosgrove SE, Harris AD, Lautenbach E, Amoah J, Avdic E, Tolomeo P, Wise J, Subudhi S, Han JH; Antibacterial Resistance Leadership Group.

JAMA Intern Med. 2019 Jan 22. doi: 10.1001/jamainternmed.2018.6226. [Epub ahead of print]

PMID:
30667477
4.

The Role of Ertapenem for the Treatment of Complicated Intra-abdominal Infections With a Positive Culture for Enterococcus faecalis.

Fabre V, Nemati K, Avdic E, Cosgrove SE, Amoah J, Tamma PD.

Open Forum Infect Dis. 2018 Dec 15;6(1):ofy339. doi: 10.1093/ofid/ofy339. eCollection 2019 Jan.

5.

Rethinking How Antibiotics Are Prescribed: Incorporating the 4 Moments of Antibiotic Decision Making Into Clinical Practice.

Tamma PD, Miller MA, Cosgrove SE.

JAMA. 2018 Dec 27. doi: 10.1001/jama.2018.19509. [Epub ahead of print] No abstract available.

PMID:
30589917
6.

Impact of a Prescriber-driven Antibiotic Time-out on Antibiotic Use in Hospitalized Patients.

Thom KA, Tamma PD, Harris AD, Dzintars K, Morgan DJ, Li S, Pineles L, Srinivasan A, Avdic E, Cosgrove SE.

Clin Infect Dis. 2018 Dec 4. doi: 10.1093/cid/ciy852. [Epub ahead of print]

PMID:
30517592
7.

Campylobacter Infections in Children.

Same RG, Tamma PD.

Pediatr Rev. 2018 Nov;39(11):533-541. doi: 10.1542/pir.2017-0285. No abstract available.

PMID:
30385582
8.

Applying Rapid Whole-Genome Sequencing To Predict Phenotypic Antimicrobial Susceptibility Testing Results among Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates.

Tamma PD, Fan Y, Bergman Y, Pertea G, Kazmi AQ, Lewis S, Carroll KC, Schatz MC, Timp W, Simner PJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01923-18. doi: 10.1128/AAC.01923-18. Print 2019 Jan.

PMID:
30373801
9.

The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.

Plazak ME, Tamma PD, Heil EL.

Expert Opin Pharmacother. 2018 Oct 22:1-13. doi: 10.1080/14656566.2018.1538354. [Epub ahead of print]

PMID:
30346216
10.

Increased 30-Day Mortality Associated With Carbapenem-Resistant Enterobacteriaceae in Children.

Chiotos K, Tamma PD, Flett KB, Karandikar MV, Nemati K, Bilker WB, Zaoutis T, Han JH.

Open Forum Infect Dis. 2018 Sep 10;5(10):ofy222. doi: 10.1093/ofid/ofy222. eCollection 2018 Oct.

11.

Two-Site Evaluation of the Colistin Broth Disk Elution Test To Determine Colistin In Vitro Activity against Gram-Negative Bacilli.

Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R, Tekle T, Campeau S, Kazmi AQ, Bell DT, Lewis S, Tamma PD, Humphries R, Hindler JA.

J Clin Microbiol. 2019 Jan 30;57(2). pii: e01163-18. doi: 10.1128/JCM.01163-18. Print 2019 Feb.

PMID:
30282791
12.

How frequently are hospitalized patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) already on contact precautions for other indications?

Goodman KE, Simner PJ, Klein EY, Kazmi AQ, Gadala A, Rock C, Tamma PD, Cosgrove SE, Maragakis LL, Milstone AM; CDC Prevention Epicenters Program.

Infect Control Hosp Epidemiol. 2018 Dec;39(12):1491-1493. doi: 10.1017/ice.2018.236. Epub 2018 Oct 1.

PMID:
30269700
13.

Single Academic Center Experience of Unrestricted β-d-Glucan Implementation.

Fabre V, Markou T, DeMallie K, Mehta S, Shoham S, Tamma PD, Zhang S, Cosgrove SE.

Open Forum Infect Dis. 2018 Aug 9;5(9):ofy195. doi: 10.1093/ofid/ofy195. eCollection 2018 Sep.

14.

Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates.

Tamma PD, Simner PJ.

J Clin Microbiol. 2018 Oct 25;56(11). pii: e01140-18. doi: 10.1128/JCM.01140-18. Print 2018 Nov. Review.

PMID:
30158194
15.

Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections.

Khamash DF, Voskertchian A, Tamma PD, Akinboyo IC, Carroll KC, Milstone AM.

J Pediatric Infect Dis Soc. 2018 Jul 13. doi: 10.1093/jpids/piy062. [Epub ahead of print]

PMID:
30011009
16.

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Tamma PD, Pierce VM, Cosgrove SE, Lautenbach E, Harris A, Rayapati D, Han JH.

Open Forum Infect Dis. 2018 Jun 8;5(6):ofy139. doi: 10.1093/ofid/ofy139. eCollection 2018 Jun.

17.

Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms.

Simner PJ, Goodman KE, Carroll KC, Harris AD, Han JH, Tamma PD.

Open Forum Infect Dis. 2018 May 17;5(5):ofy094. doi: 10.1093/ofid/ofy094. eCollection 2018 May.

18.

Ambulatory Antibiotic Stewardship through a Human Factors Engineering Approach: A Systematic Review.

Keller SC, Tamma PD, Cosgrove SE, Miller MA, Sateia H, Szymczak J, Gurses AP, Linder JA.

J Am Board Fam Med. 2018 May-Jun;31(3):417-430. doi: 10.3122/jabfm.2018.03.170225.

19.

Antibiotic pressure on the acquisition and loss of antibiotic resistance genes in Klebsiella pneumoniae.

Simner PJ, Antar AAR, Hao S, Gurtowski J, Tamma PD, Rock C, Opene BNA, Tekle T, Carroll KC, Schatz MC, Timp W.

J Antimicrob Chemother. 2018 Jul 1;73(7):1796-1803. doi: 10.1093/jac/dky121.

PMID:
29648629
20.

Reply to Chou and Trautner.

Chotiprasitakul D, Han JH, Lautenbach E, Cosgrove SE, Harris AD, Tamma PD.

Clin Infect Dis. 2018 Jul 18;67(3):483. doi: 10.1093/cid/ciy118. No abstract available.

PMID:
29617738
21.

Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.

Doernberg SB, Abbo LM, Burdette SD, Fishman NO, Goodman EL, Kravitz GR, Leggett JE, Moehring RW, Newland JG, Robinson PA, Spivak ES, Tamma PD, Chambers HF.

Clin Infect Dis. 2018 Sep 28;67(8):1168-1174. doi: 10.1093/cid/ciy255.

PMID:
29590355
22.

Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.

Tamma PD, Fan Y, Bergman Y, Sick-Samuels AC, Hsu AJ, Timp W, Simner PJ, Prokesch BC, Greenberg DE.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02213-17. doi: 10.1128/AAC.02213-17. Print 2018 Apr.

23.

Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium.

Smith TT, Tamma PD, Do TB, Dzintars KE, Zhao Y, Cosgrove SE, Avdic E.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):161-163. doi: 10.1016/j.diagmicrobio.2018.01.027. Epub 2018 Feb 3.

PMID:
29496381
24.

The Role of Negative Methicillin-Resistant Staphylococcus aureus Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy in Intensive Care Unit Patients.

Chotiprasitsakul D, Tamma PD, Gadala A, Cosgrove SE.

Infect Control Hosp Epidemiol. 2018 Mar;39(3):290-296. doi: 10.1017/ice.2017.308. Epub 2018 Jan 28.

PMID:
29374504
25.

Reply to Al-Hasan et al.

Chotiprasitakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Tamma PD.

Clin Infect Dis. 2018 Jun 1;66(12):1979-1981. doi: 10.1093/cid/ciy046. No abstract available.

PMID:
29365075
26.

Expanding Existing Antimicrobial Stewardship Programs in Pediatrics: What Comes Next.

Kronman MP, Banerjee R, Duchon J, Gerber JS, Green MD, Hersh AL, Hyun D, Maples H, Nash CB, Parker S, Patel SJ, Saiman L, Tamma PD, Newland JG.

J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):241-248. doi: 10.1093/jpids/pix104. Review.

PMID:
29267871
27.

Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.

Schuetz AN, Reyes S, Tamma PD.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01917-17. doi: 10.1128/JCM.01917-17. Print 2018 Mar.

28.

Risk Factors for Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Carriage Upon Pediatric Intensive Care Unit Admission.

Li DX, Sick-Samuels AC, Suwantarat N, Same RG, Simner PJ, Tamma PD.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):116-118. doi: 10.1017/ice.2017.246. Epub 2017 Dec 5. No abstract available.

29.

Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort.

Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, Tolomeo P, Wise J, Tamma PD; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2018 Jan 6;66(2):172-177. doi: 10.1093/cid/cix767.

30.

Implementing Antimicrobial Stewardship in Long-term Care Settings: An Integrative Review Using a Human Factors Approach.

Katz MJ, Gurses AP, Tamma PD, Cosgrove SE, Miller MA, Jump RLP.

Clin Infect Dis. 2017 Nov 13;65(11):1943-1951. doi: 10.1093/cid/cix566. Review.

31.

Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Hsu AJ, Hamdy RF, Huang Y, Olson JA, Ghobrial S, Gerber JS, Hersh AL, Tamma PD.

J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):338-341. doi: 10.1093/jpids/pix068.

PMID:
28992126
32.

Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children.

Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB, Zaoutis T, Han JH.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01440-17. doi: 10.1128/AAC.01440-17. Print 2017 Dec.

33.

Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?

Tamma PD, Wang R, Lewis S, Opene BNA, Simner PJ.

Infect Control Hosp Epidemiol. 2017 Nov;38(11):1378-1379. doi: 10.1017/ice.2017.210. Epub 2017 Oct 2. No abstract available.

34.

Sustained impact of a rapid microarray-based assay with antimicrobial stewardship interventions on optimizing therapy in patients with Gram-positive bacteraemia.

Avdic E, Wang R, Li DX, Tamma PD, Shulder SE, Carroll KC, Cosgrove SE.

J Antimicrob Chemother. 2017 Nov 1;72(11):3191-3198. doi: 10.1093/jac/dkx267.

PMID:
28961942
35.

Carbapenemase Detection among Carbapenem-Resistant Glucose-Nonfermenting Gram-Negative Bacilli.

Simner PJ, Opene BNA, Chambers KK, Naumann ME, Carroll KC, Tamma PD.

J Clin Microbiol. 2017 Sep;55(9):2858-2864. doi: 10.1128/JCM.00775-17. Epub 2017 Jul 12.

36.

Association of Adverse Events With Antibiotic Use in Hospitalized Patients.

Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE.

JAMA Intern Med. 2017 Sep 1;177(9):1308-1315. doi: 10.1001/jamainternmed.2017.1938.

37.

Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.

Tamma PD, Villegas MV.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e01094-17. doi: 10.1128/AAC.01094-17. Print 2017 Aug.

38.

Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Hamdy RF, Hsu AJ, Stockmann C, Olson JA, Bryan M, Hersh AL, Tamma PD, Gerber JS.

Pediatrics. 2017 Jun;139(6). pii: e20170183. doi: 10.1542/peds.2017-0183. Epub 2017 May 5.

39.

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Tamma PD, Rodriguez-Bano J.

Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034. Review.

40.

The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.

Anderson DJ, Jenkins TC, Evans SR, Harris AD, Weinstein RA, Tamma PD, Han JH, Banerjee R, Patel R, Zaoutis T, Lautenbach E; Stewardship and Infection Control Committeea of the Antibacterial Resistance Leadership Group (ARLG).

Clin Infect Dis. 2017 Mar 15;64(suppl_1):S36-S40. doi: 10.1093/cid/ciw830. Review.

41.

A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.

Fox MT, Melia MT, Same RG, Conley AT, Tamma PD.

Am J Med. 2017 Jul;130(7):842-845. doi: 10.1016/j.amjmed.2017.01.025. Epub 2017 Feb 16.

42.

Comparison of 11 Phenotypic Assays for Accurate Detection of Carbapenemase-Producing Enterobacteriaceae.

Tamma PD, Opene BN, Gluck A, Chambers KK, Carroll KC, Simner PJ.

J Clin Microbiol. 2017 Apr;55(4):1046-1055. doi: 10.1128/JCM.02338-16. Epub 2017 Jan 11.

43.

Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, Simner PJ.

Clin Infect Dis. 2017 Feb 1;64(3):257-264. doi: 10.1093/cid/ciw741. Epub 2016 Nov 9.

44.

What Is the More Effective Antibiotic Stewardship Intervention: Preprescription Authorization or Postprescription Review With Feedback?

Tamma PD, Avdic E, Keenan JF, Zhao Y, Anand G, Cooper J, Dezube R, Hsu S, Cosgrove SE.

Clin Infect Dis. 2017 Mar 1;64(5):537-543. doi: 10.1093/cid/ciw780.

45.

Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Buckel WR, Ghobrial S, Tamma PD, Milstone AM, Zhao Y, Hsu AJ.

Paediatr Drugs. 2017 Feb;19(1):43-51. doi: 10.1007/s40272-016-0202-4.

PMID:
27873214
46.

Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae.

Tamma PD, Huang Y, Opene BN, Simner PJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6425-9. doi: 10.1128/AAC.00838-16. Print 2016 Oct.

47.

Sustained Impact of an Antibiotic Stewardship Intervention for Community-Acquired Pneumonia.

Li DX, Ferrada MA, Avdic E, Tamma PD, Cosgrove SE.

Infect Control Hosp Epidemiol. 2016 Oct;37(10):1243-6. doi: 10.1017/ice.2016.165. Epub 2016 Aug 8.

PMID:
27498601
48.

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia.

Wang R, Cosgrove SE, Tschudin-Sutter S, Han JH, Turnbull AE, Hsu AJ, Avdic E, Carroll KC, Tamma PD.

Open Forum Infect Dis. 2016 Jun 20;3(3):ofw132. doi: 10.1093/ofid/ofw132. eCollection 2016 Sep.

49.

Use of PNA FISH for blood cultures growing Gram-positive cocci in chains without a concomitant antibiotic stewardship intervention does not improve time to appropriate antibiotic therapy.

Cosgrove SE, Li DX, Tamma PD, Avdic E, Hadhazy E, Wakefield T, Gherna M, Carroll KC.

Diagn Microbiol Infect Dis. 2016 Sep;86(1):86-92. doi: 10.1016/j.diagmicrobio.2016.06.016. Epub 2016 Jun 23.

PMID:
27412814
50.

A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.

Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH, Milstone AM, Massey CJ, Tamma PD; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2016 Oct 1;63(7):896-903. doi: 10.1093/cid/ciw425. Epub 2016 Jun 28.

Supplemental Content

Loading ...
Support Center